Based on the Sarepta Therapeutics Inc stock forecast from 18 analysts, the average analyst target price for Sarepta Therapeutics Inc is USD 184.44 over the next 12 months. Sarepta Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Sarepta Therapeutics Inc is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Sarepta Therapeutics Inc’s stock price was USD 114.23. Sarepta Therapeutics Inc’s stock price has changed by +9.27% over the past week, -13.48% over the past month and +37.84% over the last year.
No recent analyst target price found for Sarepta Therapeutics Inc
No recent average analyst rating found for Sarepta Therapeutics Inc
Company Overview Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Read Less
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat du...Read More
Frequently Asked Questions About Sarepta Therapeutics Inc (SRPT) Stock
Based on ratings from 18 analysts Sarepta Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 24 buy, sell and 8 hold ratings.
Unfortunately we do not have enough data on SRPT's stock to indicate if its a good dividend stock.
Based on targets from 18 analysts, the average taret price for SRPT is USD 184.44 over the next 12 months. The maximum analyst target price is USD 235 while the minimum anlayst target price is USD 128.
SRPT stock's Price/Earning ratio is 71.75.
Our analysis grades SRPT stock's Price / Earning ratio at F. This means that SRPT stock's Price/Earning ratio is above 88% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SRPT may be a overvalued for its sector.
The last closing price of SRPT's stock was USD 114.23.
The most recent market capitalization for SRPT is USD 10.55B.
Based on targets from 18 analysts, the average taret price for SRPT is projected at USD 184.44 over the next 12 months.
This means that SRPT's stock price may go up by +61.46% over the next 12 months.
We can't find any ETFs which contains Sarepta Therapeutics Inc's stock.
As per our most recent records Sarepta Therapeutics Inc has 1,314 Employees.
Sarepta Therapeutics Inc's registered address is 215 First Street, Cambridge, MA, United States, 02142.
You can get more information about it from Sarepta Therapeutics Inc's website at https://www.sarepta.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Sarepta Therapeutics Inc (SRPT) Stock
Based on ratings from 18 analysts Sarepta Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 24 buy, sell and 8 hold ratings.
Unfortunately we do not have enough data on SRPT's stock to indicate if its a good dividend stock.
Based on targets from 18 analysts, the average taret price for SRPT is USD 184.44 over the next 12 months. The maximum analyst target price is USD 235 while the minimum anlayst target price is USD 128.
SRPT stock's Price/Earning ratio is 71.75.
Our analysis grades SRPT stock's Price / Earning ratio at F. This means that SRPT stock's Price/Earning ratio is above 88% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SRPT may be a overvalued for its sector.
The last closing price of SRPT's stock was USD 114.23.
The most recent market capitalization for SRPT is USD 10.55B.
Based on targets from 18 analysts, the average taret price for SRPT is projected at USD 184.44 over the next 12 months.
This means that SRPT's stock price may go up by +61.46% over the next 12 months.
We can't find any ETFs which contains Sarepta Therapeutics Inc's stock.
As per our most recent records Sarepta Therapeutics Inc has 1,314 Employees.
Sarepta Therapeutics Inc's registered address is 215 First Street, Cambridge, MA, United States, 02142.
You can get more information about it from Sarepta Therapeutics Inc's website at https://www.sarepta.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SRPT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
